Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Booking Holdings Inc (BKNG) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

Booking Holdings IncTrade
Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Booking Holdings Inc vs Citius Pharmaceuticals Inc — how do they compare? Booking Holdings Inc trades at $212.74 (market cap $159.95B), while Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M). The key difference: Booking Holdings Inc is far larger — about 7993.5× Citius Pharmaceuticals Inc's market cap, and Booking Holdings Inc pays a 0.79% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

BKNGCTXR
Market Cap
$159.95B$20.01M
Sector
Consumer CyclicalHealth
52-Week High
$228.83$1.82
52-Week Low
$154.13$0.48
Enterprise Value
$163.43B$16.23M
Dividend Yield
0.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Booking Holdings Inc

BKNG trades at $212.26, down 0.29% on the day, with a bullish technical signal from moving averages and strong support at $212. The company reported Q2 2026 EPS of $2.54, beating estimates, and revenue growth remains robust, though net income margin dipped to 20.07% in 2025. Analyst consensus is strongly bullish with a $239.31 price target, and recent news highlights resilient travel demand and AI integration efforts.

The outlook for BKNG is positive, driven by earnings beats and solid cash flow, but risks include geopolitical volatility and high debt levels. Upside potential exists if travel demand sustains and margins improve, yet investors face headwinds from competitive pressures and economic sensitivity.

Citius Pharmaceuticals Inc

CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.

While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Booking Holdings Inc

Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.

Read more on BKNG

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR